ARA-290
Erythropoietin-Derived Peptide - Erythropoietin-derived peptide studied for neural repair.
ARA-290 (Cibinetide) is a synthetic peptide derived from the tertiary structure of erythropoietin, studied for its interaction with the innate repair receptor in neuropathic and inflammatory research.
ARA-290 is unusual among the catalogue in having advanced into human clinical study, where it was investigated for neuropathic and inflammatory endpoints via the tissue-protective receptor. Its design deliberately separates that repair signalling from erythropoiesis, which is what distinguishes it from erythropoietin itself.
ARA-290 specifications
- Sequence
- 11-amino-acid EPO-derived peptide
- Presentation
- Lyophilised powder
- Documented purity
- 99.89% by HPLC
- Available sizes
- 10mg ($60)
- Archived COA lots
- 1
- Intended use
- Laboratory research use only. Not for human or veterinary use.
Studied pathways
- Innate repair receptor - Selective study ligand for the tissue-protective receptor complex, without erythropoietic activity.
Reported mechanisms in the literature
- Tissue-protective signalling - Derived from the tertiary structure of erythropoietin, it is a selective study ligand for the innate repair receptor complex, without the erythropoietic (red-cell) activity of EPO. (Brines & Cerami)
ARA-290 frequently asked questions
What is ARA-290 (Cibinetide)?
ARA-290, also called Cibinetide, is an 11-amino-acid peptide derived from erythropoietin, studied for its interaction with the innate repair receptor in neuropathic and inflammatory research.
Is ARA-290 an approved drug?
No. It has been studied in clinical trials but has no marketing approval. It is supplied here for in-vitro laboratory research only.
How does it differ from EPO?
It engages the tissue-protective receptor pathway of erythropoietin without stimulating red-blood-cell production, which is the focus of much of its research interest.
Documented to 99.89% purity by HPLC · third-party COA every lot · from $60 · For laboratory research use only.
Related Regenerative & Repair compounds
- BPC-157 - Synthetic pentadecapeptide studied for VEGF and growth-factor receptor signalling.
- TB-500 - Thymosin β-4 fragment studied for actin regulation and tissue repair.
- BPC-157 / TB-500 - Co-formulated repair-research blend in a single vial.